1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
Real-time Euronext Paris  -  11:35 2022-06-29 am EDT
1.124 EUR   -0.53%
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/27Erytech's combined shareholders meeting on june 24, 2022
AQ
06/27Top Premarket Decliners
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/23/2022 06/24/2022 06/27/2022 06/28/2022 06/29/2022 Date
1.142(c) 1.142(c) 1.12(c) 1.13(c) 1.124(c) Last
33 501 14 066 60 827 15 252 6 656 Volume
+0.97% 0.00% -1.93% +0.89% -0.53% Change
More quotes
Estimated financial data (e)
Sales 2022 9,20 M 9,63 M 9,63 M
Net income 2022 -52,8 M -55,3 M -55,3 M
Net Debt 2022 1,50 M 1,57 M 1,57 M
P/E ratio 2022 -0,50x
Yield 2022 -
Sales 2023 31,6 M 33,1 M 33,1 M
Net income 2023 -41,0 M -42,9 M -42,9 M
Net Debt 2023 38,0 M 39,8 M 39,8 M
P/E ratio 2023 -0,97x
Yield 2023 -
Capitalization 34,9 M 36,5 M 36,5 M
EV / Sales 2022 3,95x
EV / Sales 2023 2,31x
Nbr of Employees 181
Free-Float 98,5%
More Financials
Company
ERYTECH Pharma S.A. is a biopharmaceutical company in the clinical stage that develops innovative therapies based on red blood cells to fight cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, a new technology for encapsulating drugs in red blood cells, ERYTECH Pharma S.A. is developing a portfolio of product candidates targeting markets with significant unmet medical needs. eryaspase, the... 
More about the company
Ratings of ERYTECH Pharma S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ERYTECH PHARMA S.A.
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/27Erytech's combined shareholders meeting on june 24, 2022
AQ
06/27Top Premarket Decliners
MT
06/24Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022
GL
06/24Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022
AQ
06/23European ADRs Move Lower in Thursday Trading
MT
06/17European ADRs Move Lower in Friday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14European ADRs Move Lower in Tuesday Trading
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/07European ADRs Move Higher in Tuesday Trading
MT
06/02European ADRs Nudge Lower in Thursday Trading
MT
06/02Top Premarket Decliners
MT
05/31European ADRs Nudge Higher in Tuesday Trading
MT
05/31ERYTECH PHARMA S.A. : Monthly statement on outstanding equity shares and voting rights
CO
More news
News in other languages on ERYTECH PHARMA S.A.
06/28Les ADR européens en baisse dans les échanges de mardi
06/24Compte Rendu – Assemblée Générale Mixte d'ERYTECH du 24 Juin 2022
06/23Les ADR européens sont en baisse jeudi
06/17Les ADR européens sont en baisse vendredi
06/15Les ADR européens sont en hausse mercredi
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 1,12 €
Average target price 3,60 €
Spread / Average Target 220%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-46.98%37
GILEAD SCIENCES, INC.-13.95%78 031
VERTEX PHARMACEUTICALS27.66%70 632
REGENERON PHARMACEUTICALS, INC.-5.37%64 046
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979